To increase national health security against biothreats and protect public health, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response, awarded an initial two-year, $10 million contract to Public Health Vaccines, LLC of Cambridge, Massachusetts, to develop a potential vaccine against Marburg virus. No licensed vaccine for this virus exists today.

The Marburg virus is part of the family of hemorrhagic fever viruses that includes Ebola. The virus causes a similar illness to that of Ebola, and occurs most often in Africa. The Marburg virus was recognized in 1967 and since then multiple outbreaks have occurred with high mortality rates, most recently in 2017.

Controlled Substances and
Emergency Response Fact Sheet:
Frequently Asked Questions

Challenges of No-Notice Events
for Hospital Support
Services Staff

Hospital-Based Incident
Command Systems: Best Practices,
Lessons Learned from Small
and Rural Hospitals

Evacuating, Treating, and
Tracking People on Dialysis:
Lessons Learned from the
2017 Hurricane Season